Capecitabine (Oral Chemotherapy) – Patient Information (Australia)

Capecitabine is a medicine used to treat certain cancers. It is taken by mouth and works by being converted in the body to an active chemotherapy drug that targets cancer cells. This page is designed to be patient-friendly and to help you understand how capecitabine works, how it is usually taken, what to expect, and what to discuss with your healthcare team.

Quick overview

• Medicine name: Capecitabine
• How it’s taken: Oral tablets
• Common role: Treatment for selected solid tumours (e.g., breast, colorectal, gastric cancers)
• How it works: Converted to a chemotherapy agent in the body, with greater activation in tumour tissue
• Typical schedule: Often taken in cycles (e.g., 2 weeks on, 1 week off), depending on your regimen

Basic product information

Brand names: Capecitabine may be supplied under various brand names depending on the manufacturer and supplier in Australia.

What it contains: Capecitabine is the active ingredient.

Form: Tablets

Strengths: Tablet strengths vary by product (your pharmacist or packaging will confirm the exact strength).

Who supplies it: Typically dispensed through pharmacy supply channels for oncology care.

Important: Always follow the directions provided with your specific supply and your healthcare team’s instructions.

Mechanism of action (how capecitabine works)

Capecitabine is a prodrug, meaning it is converted into its active form inside the body. After absorption, capecitabine is metabolised through a multi-step process to form 5-fluorouracil (5-FU), a chemotherapy drug.

A key feature is that activation is often higher in tumour tissue. Tumour cells (and the surrounding environment) contain higher levels of enzymes involved in converting capecitabine to 5-FU. This can help the medicine concentrate its anti-cancer activity where it is most needed.

• Active effect: 5-FU interferes with cancer cell growth by disrupting DNA and RNA processes.
• Why it matters: Rapidly dividing cancer cells are more vulnerable to these effects.

Pharmacokinetics (what the body does with capecitabine)

While individual responses vary, the general pharmacokinetic behaviour of capecitabine is well described. Understanding this helps explain timing with meals and the importance of consistent dosing.

• Absorption: Capecitabine is absorbed from the gastrointestinal tract.
• Distribution: It circulates as a prodrug and its metabolites, reaching tissues throughout the body.
• Metabolism: It is metabolised in the liver and other tissues through enzymatic steps.
• Activation: Conversion to 5-FU occurs progressively, with increased activation in tumour tissues due to enzyme activity.
• Excretion: Metabolites are eliminated primarily through the kidneys.

Because excretion is influenced by kidney function, dose adjustments may be considered in people with reduced renal clearance. Your clinician may also monitor blood tests during treatment.

Typical use in cancer care

Capecitabine is used in various cancer settings, including:

• Colorectal cancer: Often as adjuvant therapy (after surgery in selected situations) or for advanced/metastatic disease.
• Breast cancer: Commonly in specific stages and treatment plans, including in combination regimens.
• Gastric (stomach) cancer: In certain lines of therapy and combination regimens.
• Other solid tumours: Use depends on clinical guidelines, tumour characteristics, and treatment history.

Your exact purpose—curative/adjuvant, palliative, or part of a combination regimen—depends on diagnosis, stage, prior treatments, and overall health.

Indications (when it may be prescribed)

In Australia, capecitabine is used for eligible patients under established oncology protocols and clinical guidance. Indications can vary based on treatment line and combination therapy.

Commonly, capecitabine is indicated for:

• Adjuvant treatment for colorectal cancer in appropriate patients
• Metastatic colorectal cancer (sometimes in combination depending on the regimen)
• Breast cancer (including in metastatic settings or as part of selected combination approaches)
• Gastric cancer in particular treatment contexts

Your oncology team will confirm whether capecitabine is appropriate for your specific diagnosis and regimen.

Dosing and timing (how to take it safely)

Capecitabine dosing is tailored to your treatment plan and usually calculated based on body surface area (BSA). It may be taken in cycles (for example, 2 weeks on treatment followed by 1 week off), but other schedules are also used.

Follow your personalised instructions exactly. Do not adjust your dose unless your healthcare team tells you to.

Typical scheduling patterns

• Common regimen: Often twice daily on a schedule such as “days 1–14 on, days 15–21 off” (example only).
• Other regimens: May be modified depending on cancer type, combinations, tolerability, and blood results.

When to take tablets

Capecitabine is typically taken twice a day, with a consistent interval between doses. Your regimen will state the specific days of each cycle.

Many people find it easiest to take doses in the morning and evening at set times to maintain consistency. If you miss a dose, do not “double up”—contact your healthcare team or pharmacist for advice.

How to take

• Swallow tablets whole with water.
• Keep tablets in their original packaging and store as directed on the label.
• Do not crush or break tablets unless your clinician has advised a specific approach.

Food interactions (meal timing and consistency)

Food can affect how capecitabine is absorbed. For many regimens, clinicians advise taking capecitabine after food to reduce stomach upset and improve absorption reliability.

• General patient guidance: Take capecitabine after a meal (or with food), as directed by your clinician or the product instructions.
• Consistency matters: Try to take doses at similar meal times each day.

If you have difficulty eating, experience nausea, or have appetite changes, discuss this with your oncology team. They can help you manage side effects while maintaining safe dosing.

Alcohol interactions

Alcohol does not have a single universally described direct interaction with capecitabine, but it can increase the risk of side effects and may worsen treatment tolerance.

• Potential concerns: increased nausea/vomiting, dizziness, tiredness, dehydration, and liver stress in some people.
• Practical approach: If you choose to drink alcohol, do so cautiously and only if your healthcare team says it is acceptable.
• Hydration: Maintain adequate fluid intake, especially if you experience diarrhoea or mouth sores.

Tell your clinician about your alcohol intake and any liver or kidney issues. Adjustments may be required.

Other medicine interactions (tell your doctor and pharmacist)

Capecitabine can interact with other medicines, including those that affect liver enzymes or blood thinning. Always provide a full list of your medicines to your pharmacist and oncology team.

Important interaction categories

• Anticoagulants (blood thinners): Some patients may require close monitoring if using warfarin or other agents, due to potential changes in bleeding risk.
• Leucovorin/folate-related therapies: These may alter how 5-FU behaves in combination regimens (commonly handled by oncology protocols).
• Anti-nausea medicines and supportive care: Often used safely, but dosing and side effects should be reviewed.
• Kidney-impacting medicines: Since metabolites are excreted through the kidneys, medicines that affect kidney function may matter.
• Allopurinol and other metabolism-affecting drugs: Can require caution depending on your overall regimen.

If you start any new medication (including over-the-counter medicines, herbal products, or supplements), ask your pharmacist whether it is safe to combine with capecitabine.

Safety profile (what to expect and when to seek help)

Like many chemotherapy agents, capecitabine can cause side effects. Not everyone experiences all side effects, and severity varies widely between individuals. Your oncology team will monitor you and may adjust dose or schedule if needed.

Common side effects

• Diarrhoea or changes in bowel habits
• Hand–foot syndrome (palmar-plantar erythrodysaesthesia): redness, swelling, pain, or peeling of skin on hands/feet
• Nausea, sometimes vomiting
• Mouth sores (stomatitis)
• Fatigue
• Loss of appetite
• Skin changes and dryness
• Low blood counts (may affect infection risk and bruising/bleeding)

Serious side effects (seek urgent medical advice)

Contact emergency services or urgent medical care if you develop severe symptoms. Examples include:

• Severe diarrhoea or signs of dehydration (dizziness, fainting, very low urine output)
• Severe hand–foot syndrome affecting daily function
• Fever or infection symptoms (especially if you have low white blood cells)
• Chest pain, shortness of breath, or unusual neurologic symptoms
• Severe mouth sores preventing fluids/food
• Bleeding that is unusual or cannot be controlled

Monitoring during treatment

• Blood tests: to check blood counts and organ function
• Renal function: kidney function is especially important
• Side effect assessments: skin, gut, mouth, and overall tolerance

Practical use tips (daily life with capecitabine)

Skin care to reduce hand–foot syndrome

• Keep hands and feet moisturised using fragrance-free creams.
• Avoid friction and pressure: wear comfortable, well-fitted shoes.
• Limit hot water soaks; prefer lukewarm showers.
• Be gentle with washing and drying; pat dry rather than rubbing.

Managing diarrhoea

• Start early symptom reporting to your oncology team.
• Use fluids and oral rehydration solutions if you’re advised to.
• Avoid foods that worsen diarrhoea (your dietitian/clinician can guide you).
• Only use anti-diarrhoea medicines if your clinician recommends them for your situation.

Mouth care

• Brush gently with a soft toothbrush.
• Use recommended mouth rinses to reduce irritation.
• Report painful sores early, especially if you can’t eat or drink comfortably.

Energy and wellbeing

• Plan rest periods during the days of treatment.
• Ask your care team about safe exercise or physiotherapy if you feel up to it.
• Seek support for emotional wellbeing—cancer care can be challenging.

Medication handling and hygiene

• Wash hands after handling tablets.
• Store tablets securely away from children and pets.
• If a tablet is broken or spilled, follow pharmacy instructions for safe cleanup.

Dose modification and treatment interruptions

Because capecitabine can affect the skin, gastrointestinal tract, and blood counts, clinicians may:

• Delay the next cycle
• Reduce the dose
• Shorten or adjust the on-treatment days

These steps help manage side effects and reduce risk of complications. Never change your schedule on your own—always speak with your oncology team.

Alternative options (discuss with your clinician)

Alternative treatments depend on the cancer type, stage, and previous therapies. Your clinician may consider other oral or infusion chemotherapy options, targeted therapies, immunotherapy, or combinations.

Examples of alternatives (not exhaustive)

• 5-fluorouracil (5-FU) or capecitabine-related regimens using different schedules
• Other chemotherapy agents commonly used for colorectal, breast, and gastric cancers
• Targeted therapies where specific biomarkers match eligible criteria
• Immunotherapy for certain tumour types and characteristics

Your oncology team can explain which options are available for your diagnosis and why capecitabine may be chosen.

Market and legal context in Australia (high-level)

In Australia, medicines are regulated by the Therapeutic Goods Administration (TGA), and supply is governed by national medicine scheduling and pharmacy dispensing rules. Cancer medicines like capecitabine are typically supplied via approved channels with appropriate prescribing and clinical oversight.

Additional support may be available through oncology services, including access programs and hospital-based pathways for ongoing monitoring and supportive care. Always follow Australian healthcare guidance and your treating team’s instructions.

Recent guidance and evolving care (what patients should watch for)

Oncology practice can evolve based on new evidence and updated clinical guidelines. Over time, protocols may include:

• Refined dose adjustments for kidney function and treatment-related toxicities
• Improved supportive care strategies (e.g., managing diarrhoea, hand–foot syndrome, mouth sores)
• More emphasis on early symptom reporting to prevent severe complications

If you are unsure whether your regimen has recently changed, ask your oncology team or pharmacist. They can clarify your cycle schedule and supportive medications.

Delivery and availability (Australia)

Capecitabine availability depends on supply schedules and the specific brand/strength dispensed. Online pharmacy ordering may involve verification steps and coordination with dispensing pharmacies where required.

What you can expect

• Stock checks: The pharmacy may confirm availability for your required strength and quantity.
• Packaging: Tablets are typically supplied in original manufacturer packaging.
• Cold chain: Capecitabine generally does not require refrigeration, but always check your product label.
• Tracking and delivery estimates: Delivery timelines vary by location.

If your treatment is time-critical (e.g., starting a new cycle), contact customer support so your order can be prioritised and verified.

Frequently Asked Questions (FAQ)

1) What is capecitabine used for?

Capecitabine is used to treat selected cancers, including colorectal, breast, and gastric cancers, in specific stages and treatment combinations. The exact indication depends on your diagnosis and treatment plan.

2) How do I take capecitabine?

It is taken by mouth as tablets. Doses are typically scheduled twice daily and often taken after food. Your regimen may follow cycles (e.g., on-treatment days followed by rest days). Follow the instructions provided with your supply.

3) Can I take capecitabine with food?

Many patients are instructed to take capecitabine after meals. Food timing can influence absorption and stomach comfort. Ask your pharmacist or clinician for your specific meal-time guidance.

4) What should I do if I miss a dose?

Do not double up. Contact your pharmacist or oncology team for advice on what to do next, because missing doses can affect your cycle plan.

5) What is hand–foot syndrome, and how can I reduce it?

Hand–foot syndrome is a common capecitabine side effect causing redness, swelling, pain, or peeling of the skin on hands and feet. Moisturising, avoiding friction/pressure, and reporting early symptoms to your healthcare team can help manage it.

6) Is it safe to drink alcohol?

Alcohol may increase side effects such as nausea and fatigue. There is no single universal rule, but it’s safest to discuss alcohol with your clinician. If advised to avoid alcohol, follow that advice.

7) What medicines interact with capecitabine?

Interactions can occur with blood thinners and other medications. Tell your pharmacist about all medicines, including over-the-counter products and herbal supplements, so they can check for interactions.

8) How long does a treatment cycle last?

Cycles vary by regimen. Many schedules follow a pattern such as two weeks on treatment and one week off, but your personal schedule may differ. Your oncology team will give you your exact calendar.

9) When should I seek urgent medical help?

Seek urgent care if you develop severe diarrhoea, signs of dehydration, fever or infection symptoms, severe mouth sores preventing fluids, uncontrolled bleeding, or severe worsening skin reactions. When in doubt, contact your healthcare team promptly.

10) Are there alternatives to capecitabine?

Yes—options may include other chemotherapy agents, targeted therapies, immunotherapy, or different chemotherapy schedules. Alternatives depend on your cancer type, biomarkers, stage, and prior treatments.

Summary table: key points at a glance

Important note: This information is general and cannot replace advice from your oncology team or pharmacist. If you have questions about your specific regimen, dosing schedule, or side effects, contact your healthcare provider.